Loading…
NITROSTAT is a brand name for Nitroglycerin, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Verbatim from this product's HC label. Tap a section to expand.
Headache, which may be severe and persistent may occur immediately after use. Vertigo, dizziness, weakness, palpitation, and other manifestations of postural hypotension may develop occasionally, particularly in erect, immobile patients.
Marked sensitivity to the hypotensive effects of nitrates (manifested by nausea, vomiting, weakness, diaphoresis, pallor and collapse) may occur at therapeutic doses. Syncope due to nitrate vasodilation has been reported. Flushing, drug rash, exfoliative dermatitis, and urticaria have been reported in patients receiving nitrate therapy.
Paradoxical bradycardia and increased angina pectoris may accompany nitroglycerin-induced hypotension. (See PRECAUTIONS) SYMPTOMS AND TREATMENT OF OVERDOSAGE Hemodynamic Effects: The effects of nitroglycerin overdose are generally the results of nitroglycerin’s capacity to induce vasodilatation, venous pooling, reduced cardiac output, and hypotension.
These hemodynamic changes may have protean manifestations, including increased intracranial pressure, with any or all of persistent throbbing headache, confusion, and moderate fever; vertigo; palpitations; tachycardia; visual disturbances; nausea and vomiting (possibly with colic and even bloody diarrhea); syncope (especially in the upright posture); dyspnea, later followed by reduced ventilatory effort, diaphoresis, with the skin either flushed or cold and clammy; heart block and bradycardia; paralysis; coma; seizures; and death.
No specific antagonist to the vasodilator effects of nitroglycerin is known, and no intervention has been subject to controlled study as a therapy of nitroglycerin overdose. Because the hypotension associated with nitroglycerin overdose is the result of venodilatation and arterial hypovolemia, prudent therapy in this situation should be directed toward increase in central fluid volume.
Passive elevation of the patient’s legs may be sufficient, but intravenous infusion of normal saline or similar fluid may also be necessary. The use of epinephrine or other arterial vasoconstrictors in this setting is likely to do more harm than good.
In patients with renal disease or congestive heart failure, therapy resulting in central volume expansion is not without hazard. Treatment of nitroglycerin overdose in these patients may be subtle and difficult, and invasive monitoring may be required.
NITROSTAT (nitroglycerin) – Prescribing Information Page 9 of 16 Methemoglobinemia: Methemoglobinemia has been rarely reported in association with organic nitrates. The diagnosis should be suspected in patients who exhibit signs of impaired oxygen delivery despite adequate cardiac output and adequate arterial PO2.
Classically, methemoglobinemic blood is described as chocolate brown, without color change on exposure to air. If methemoglobinemia is present, intravenous administration of methylene blue, 1 to 2 mg/kg of body weight, may be required.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Nitroglycerin in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
6 mg. One tablet should be dissolved under the tongue or in the buccal pouch at the first sign of an acute anginal attack. The dose may be repeated approximately every five minutes, until relief is obtained. If the pain persists after a total of 3 tablets in a 15-minute period, prompt medical attention is recommended.
NITROSTAT (nitroglycerin sublingual tablets) may be used prophylactically five to ten minutes prior to engaging in activities which might precipitate an acute attack. During administration for an acute angina attack, the patient should rest, preferably in the sitting position.
No dosage adjustment is required in patients with renal failure. 09 Description: Nitroglycerin is an organic nitrate. It is a pale yellow oily liquid which is soluble in water, ethanol and methanol. 6 mg. Non-medicinal ingredients: calcium stearate, glyceryl monostearate, lactose monohydrate, pregelatinized starch, silicon dioxide.
Gluten-, paraben-, sodium-, sulfite- and tartrazine-free. Bottles of 100. NITROSTAT is a stabilized sublingual compressed nitroglycerin tablet. This compressed tablet formulation is more stable and more uniform than conventional moulded tablets.
H 2C - O - NO2 HC - O - NO2 H 2C - O - NO2 NITROSTAT (nitroglycerin) – Prescribing Information Page 11 of 16 AVAILABILITY OF DOSAGE FORMS NITROSTAT (nitroglycerin sublingual tablets) are available as small, round, white sublingual tablets in amber glass bottles of 100.
6 mg nitroglycerin. 3 mg tablet is marked with “N” on one side and the number “3” on the other side. 6 mg tablet is marked with “N” on one side and the number “6” on the other side.
TOXICOLOGY Carcinogenesis/Mutagenesis:
Animal carcinogenesis studies with sublingually administered nitroglycerin have not been performed. Carcinogenicity potential of nitroglycerin was evaluated in rats receiving up to 434 mg/kg/day of dietary nitroglycerin for 2 years.
Rats developed dose-related fibrotic and neoplastic changes in liver, including carcinomas, and interstitial cell tumors in testes. At high dose, the incidence of hepatocellular carcinomas in males was 48% and in females was 33% compared to 0% in untreated controls.
Incidences of testicular tumors were 52% vs 8% in controls. Lifetime dietary administration up to 1058 mg/kg/day of nitroglycerin was not tumorigenic in mice. Nitroglycerin was weakly mutagenic in Ames tests performed in 2 different laboratories.
Nevertheless, there was no evidence of mutagenicity in an in vivo dominant lethal assay with male rats treated with doses up to about 363 mg/kg/day, PO, or in […]